profit from every $100 of sales.
$0$100
NuCana
$0.94+0.50% today
-74.7% in 1 year
1-year low $0.931-year high $4.43
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What NuCana sold, what it kept, and what it did with the cash.
Sales went from £0 in 2022 to £0 in 2025, with -£29.4 million of profit last year.
SalesProfit
NuCana vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| NuCana | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads NuCana's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -44 | -31 | -23 | -21 | |
| -43 | -31 | -22 | -21 | |
| -32 | -28 | -19 | -29 | |
| -3,050.00 | -2,650.00 | -1,300.00 | 0.00 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 58 | 28 | 15 | 30 |
| Cash | 42 | 17 | 7 | 24 |
| Total debt | 1 | 0 | 0 | 1 |
| Total liabilities | 20 | 13 | 9 | 6 |
| 39 | 15 | 6 | 24 | |
| 0 | 0 | 0 | 4 | |
| -88.2% | -160.9% | -295.8% | -65.8% | |
| -83.2% | -185.6% | -319.1% | -120.7% |
Cash flow
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -23 | -26 | -19 | -7 | |
| 1 | 0 | 0 | 0 | |
| -24 | -27 | -19 | -8 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 4 | 2 | 10 |
Valuation
- –
- –
- –
- 0.2×
- –
- –
- 0.7×
- -236.2%
- -974.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -70.2%
- -149.7%
- -189.9%
- -98.5%
- -73.1%
- –
Growth
- –
- –
- +64.1%
- –
- −2.9%
Financial health
- 1.1×
- 0.03
- 2.3%
- –
- 5.60
- 5.60
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 958
Bottom 21%of 889
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -1.25 | -2.64 | +52.7% |
| Mar 19, 2026 | -1.47 | -2.69 | +45.4% |
| Nov 13, 2025 | -0.10 | -2.69 | +96.3% |
| Aug 20, 2025 | -0.16 | -2.75 | +94.2% |
| Jun 2, 2025 | -126.00 | -2.58 | −4,778.0% |
| Mar 20, 2025 | -64.00 | -486.00 | +86.8% |
| Nov 25, 2024 | -456.00 | -3.47 | −13,041.2% |
| Aug 15, 2024 | -758.00 | -710.00 | −6.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
78Pass
Philip Fisher
34No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
28No pass
Terry Smith
23No pass
Questions about NuCana
Is NuCana a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the NuCana AI analysis
What does NuCana do?
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. It is in Biotechnology.
Does NuCana pay a dividend?
No. NuCana does not pay a dividend at the moment.
Is NuCana stock halal?
No. NuCana does not pass our halal screen: its cash and confirmed interest-bearing investments are 823% of its market value, at or above the 33% limit. How we check
How has NuCana stock done over the past year?
Down 74.7% over the past twelve months, to $0.94. It traded between $0.93 and $4.43 and is 78.8% below its high.
Who are NuCana's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with NuCana's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.